OnkosXcel

OnkosXcel Therapeutics, Inc., a clinical-stage independent private subsidiary of BioXcel Therapeutics, Inc., is focused on leveraging artificial intelligence approaches to develop transformative drugs in oncology. The subsidiary was established to develop BXCL701, a Phase 2, investigational, orally administered systemic innate immune activator for the treatment of aggressive prostate cancer and advanced solid tumors.